{"id":37321,"date":"2026-05-10T10:28:00","date_gmt":"2026-05-10T14:28:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=37321"},"modified":"2026-03-10T23:08:01","modified_gmt":"2026-03-11T03:08:01","slug":"pick-the-right-patent-or-leave-billions-on-the-table-the-definitive-guide-to-the-one-patent-per-product-rule-and-pte-selection-strategy","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/pick-the-right-patent-or-leave-billions-on-the-table-the-definitive-guide-to-the-one-patent-per-product-rule-and-pte-selection-strategy\/","title":{"rendered":"Pick the Right Patent Or Leave Billions on the Table: The Definitive Guide to the One-Patent-Per-Product Rule and PTE Selection Strategy"},"content":{"rendered":"\n

The Decision That Defines Decades of Revenue<\/strong><\/h1>\n\n\n\n
\"\"<\/figure>\n\n\n\n

Somewhere between the FDA approval notice hitting a pharmaceutical company’s inbox and the 60-day statutory deadline to file a patent term extension (PTE) application, one of the most consequential decisions in drug commercialization gets made. Which patent do you extend?<\/p>\n\n\n\n

For most drugs, the answer appears obvious: extend the compound patent, the fundamental claim on the active ingredient itself. In practice, the decision is rarely obvious, and the difference between the optimal and the suboptimal choice can run into the hundreds of millions to billions of dollars in protected revenue. A drug generating $8 billion annually produces roughly $22 million per day. An extension selection that is two years suboptimal compared to the alternative costs $16 billion. That is not a rounding error. It is a strategic failure of the first order.<\/p>\n\n\n\n

The constraint driving this decision is statutory. Under 35 U.S.C. Section 156, a product can receive only one patent term extension. Congress wrote that restriction in 1984 as a check against unlimited exclusivity accumulation. The intent was reasonable. The consequence — that every applicant must pick a single patent from potentially dozens of eligible candidates — creates an optimization problem that most pharmaceutical companies underestimate and many pharmaceutical counsel have never fully analyzed.<\/p>\n\n\n\n

This article breaks down how the selection framework works, which factors drive the optimal choice, why companies get it wrong with costly regularity, and what the most sophisticated patent managers do differently when facing the one-patent-per-product constraint. The analysis draws on case studies spanning small-molecule blockbusters, biologics, and combination products, supplemented by data from the USPTO’s patent term restoration database, the FDA’s Orange Book and Purple Book, and patent analytics platforms including DrugPatentWatch.<\/p>\n\n\n\n

The audience for this analysis is patent counsel, pharmaceutical business development executives, IP strategists, and investors who need to evaluate whether a company’s PTE selection has maximized or squandered the value of a given drug’s exclusivity window. The stakes justify the rigor.<\/p>\n\n\n\n

The One-Patent Rule: What the Statute Actually Says<\/strong><\/h1>\n\n\n\n

Reading 35 U.S.C. Section 156 Precisely<\/strong><\/h2>\n\n\n\n

The patent term restoration provisions in 35 U.S.C. Section 156 occupy roughly 3,000 words of statutory text. Within those 3,000 words, the one-patent constraint appears in Section 156(c)(4), which states that the period of extension shall not be granted for a patent if the product has already been the subject of a patent extension. The term “product” in this context means the active ingredient or active moiety in the approved drug. One active ingredient, one extension. No exceptions, no waivers, no do-overs.<\/p>\n\n\n\n

The statute does not restrict the number of patents that can exist on a drug. A new molecular entity approved by the FDA might have 20 or 30 patents listed in the Orange Book covering the compound, multiple methods of treatment, formulations, dosing regimens, manufacturing processes, and polymorphs. Each of those 20 or 30 patents may technically qualify for a PTE under Section 156(a). The applicant chooses one, and that choice is permanent. If the chosen patent is later invalidated, the right to extend a different patent does not revive. The product has “already been the subject” of an extension, even if that extension was subsequently vacated. That interpretation has been confirmed by the USPTO and courts in multiple proceedings [1].<\/p>\n\n\n\n

What Makes a Patent Eligible in the First Place<\/strong><\/h2>\n\n\n\n

Before the selection decision can be made, the applicant must identify which patents are eligible. Section 156(a) sets four conditions for eligibility. The patent must claim the approved product, a method of using the approved product, or a method of manufacturing the approved product. The patent must be in force at the time of application. The commercial marketing of the product in the U.S. must not have begun before approval. The patent term must not have previously been extended under Section 156.<\/p>\n\n\n\n

In practice, the eligibility filter eliminates some candidates immediately. Patents that expired before the NDA or BLA was submitted are out. Patents that do not claim the approved product as approved are out. Manufacturing patents that cover only intermediate chemical steps unrelated to the final approved product are out. The set of remaining eligible patents is the candidate pool from which the selection must be made.<\/p>\n\n\n\n

The phrase “as approved” creates important nuance. A patent that covers a broad class of compounds including the approved drug may not satisfy the eligibility test if the approved specific compound is not recited or clearly encompassed by the claims as written at the time of filing the patent. This eligibility question is separate from the infringement question, and generic manufacturers challenging PTEs have successfully argued that a patent that would technically be infringed by the drug does not satisfy the Section 156(a) eligibility criteria because the claims are drafted in terms of a broader class rather than the specific approved product.<\/p>\n\n\n\n

The Regulatory Review Period: How It Differs by Patent Type<\/strong><\/h3>\n\n\n\n

The extension calculation depends on the “regulatory review period” as defined for the specific approved use of the product. Importantly, this calculation is the same regardless of which eligible patent is selected. The regulatory review period is a property of the product and its approval process, not of any particular patent. The FDA calculates it based on the date of the IND filing, the date of the NDA filing, and the date of approval.<\/p>\n\n\n\n

The extension added to any selected patent is therefore: one-half of Phase I testing time plus all of Phase II review time, minus any applicant delay reductions. This figure typically produces an extension between two and three years for standard new molecular entities. The maximum is five years. This calculation does not change based on the patent selected. What changes across patents is their current term length, and therefore their extended expiration date.<\/p>\n\n\n\n

Why “Earlier-Expiring” Is Not Always “Better”<\/strong><\/h3>\n\n\n\n

A common misunderstanding in PTE selection is that the longest possible extension automatically yields the most commercial value. That would be true if extension value were purely a function of extension duration. It is not. The commercial value of a patent extension is the product of two variables: extension duration and daily revenue during that extended period. A patent whose term ends in 2035 with a 2.5-year extension expires in 2037 with 2.5 years of protection. A different patent whose term ends in 2030 with a 3-year extension expires in 2033 with 3 years of protection. The former may produce more total protected revenue if the drug’s market position is stronger in the 2035 to 2037 window than it is in the 2030 to 2033 window.<\/p>\n\n\n\n

The selection decision is therefore a discounted cash flow problem disguised as a patent question. Every company that approaches it as purely a patent question, asking “which selection gives us the most days,” without modeling the revenue associated with those days, is solving the wrong problem.<\/p>\n\n\n\n

The Three Patent Classes and Their Selection Profiles<\/strong><\/h1>\n\n\n\n

Compound Patents: The Presumptive Default<\/strong><\/h2>\n\n\n\n

The compound patent, also called the composition-of-matter or NCE (new chemical entity) patent, covers the active ingredient itself. It is the broadest claim available, typically filed early in the development process when the company first synthesizes or acquires rights to the molecule. Its breadth makes it the most commercially powerful patent in the portfolio and the most frequently selected for PTE.<\/p>\n\n\n\n

The compound patent is frequently the optimal selection because it is the most expensive to design around. A generic manufacturer cannot launch a bioequivalent product without infringing the compound patent, regardless of how it formulates or administers the drug. Method-of-treatment and formulation patents can sometimes be avoided through skinny labeling or alternative delivery routes; the compound patent cannot. This makes compound patents the most likely to generate full commercial protection during their extended term.<\/p>\n\n\n\n

The compound patent also tends to be the most litigated. It is the primary target of Paragraph IV certifications because invalidating it opens the market completely. Brand companies therefore face a trade-off: the compound patent provides the broadest protection but also attracts the highest volume and most intense litigation. A company selecting a compound patent for PTE extension must assess whether the patent will survive an aggressive challenge campaign during the extended period.<\/p>\n\n\n\n

Method-of-Treatment Patents: The Strategic Fallback<\/strong><\/h2>\n\n\n\n

A method-of-treatment patent covers the use of the compound for a specific therapeutic indication. When the compound patent is expiring sooner, or has already expired, or has been invalidated, the method-of-treatment patent becomes the most commercially important remaining barrier to competition. For drugs that earned new indications years after initial approval, the method-of-treatment patents covering those new indications may expire substantially later than the original compound patent, creating the possibility of selecting a method-of-treatment patent for PTE and extending protection well beyond what the compound patent would have allowed.<\/p>\n\n\n\n

The selection of a method-of-treatment patent introduces a different commercial risk: generic skinny labeling. A generic manufacturer can launch a product with a label that excludes the patented indication, relying on off-label prescribing to capture a significant fraction of the branded market. If a substantial portion of the drug’s prescribing is for the protected indication, this risk is bounded; if prescribing is concentrated in unprotected indications, the method-of-treatment patent provides thin commercial protection despite its legal existence.<\/p>\n\n\n\n

Courts in the United States and Europe have spent years developing the jurisprudence around skinny labeling. The U.S. Federal Circuit’s Glaxo v. Apotex line of cases and the UK Supreme Court’s 2018 decision in Warner-Lambert v. Generics both addressed variants of this question. The U.S. position generally requires proof of specific intent to infringe the patented use, creating a litigation burden on brand companies that makes method-of-treatment patents less commercially robust than compound patents, even when they provide technically valid legal claims.<\/p>\n\n\n\n

Method-of-Manufacture Patents: The Underused Option<\/strong><\/h2>\n\n\n\n

Method-of-manufacture patents cover the process by which the active ingredient or the finished dosage form is produced. For small molecules, these patents are often the weakest candidates for PTE selection because generic manufacturers can frequently develop alternative synthesis routes that avoid the patented process. A generic company that files a Paragraph IV certification against a manufacturing process patent typically argues non-infringement rather than invalidity, claiming that its own synthesis route does not use the patented steps.<\/p>\n\n\n\n

For biologics, the picture changes substantially. Biologic drugs are produced through complex cell culture, fermentation, and purification processes that are difficult to replicate exactly. Manufacturing patents on biologic production processes can be technically very difficult to design around, making them commercially meaningful exclusivity barriers. For a biologic whose compound patent has a short extension calculation but whose manufacturing process patent has a longer remaining term, the manufacturing process patent may be the optimal PTE selection.<\/p>\n\n\n\n

The underuse of manufacturing patents as PTE candidates reflects a broader organizational problem in pharmaceutical IP management: the people who understand manufacturing process patents best are typically process chemistry or biologics manufacturing specialists who are not involved in the commercial IP strategy decisions that govern PTE selection. Bridging that organizational gap is one of the more concrete recommendations in this analysis.<\/p>\n\n\n\n

Summary Comparison of Patent Classes for PTE Selection:<\/strong><\/p>\n\n\n\n

Patent Type<\/strong><\/th>Eligible for PTE?<\/strong><\/th>Avg. Extension (yrs)<\/strong><\/th>Challenge Rate<\/strong><\/th>Best Use Case<\/strong><\/th><\/tr><\/thead>
Compound \/ NCE<\/td>Yes<\/td>2.5-3.5<\/td>High (Para IV)<\/td>Primary selection for most NMEs<\/td><\/tr>
Method-of-Treatment<\/td>Yes<\/td>2.0-3.0<\/td>Moderate<\/td>When compound patent expired or weak<\/td><\/tr>
Method-of-Manufacture<\/td>Yes<\/td>1.5-2.5<\/td>Low-Moderate<\/td>Manufacturing-intensive biologics<\/td><\/tr>
Formulation \/ Composition<\/td>Yes (if approved product)<\/td>1.5-2.5<\/td>Moderate-High<\/td>New delivery systems, prodrugs<\/td><\/tr>
Polymorph \/ Salt Form<\/td>Conditional<\/td>1.0-2.0<\/td>Very High<\/td>Rarely optimal; last resort<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Sources: USPTO patent term restoration database, FDA Orange Book, DrugPatentWatch [2], author analysis.<\/em><\/p>\n\n\n\n

A Framework for PTE Selection: Four Steps<\/strong><\/h1>\n\n\n\n

Step 1: Build the Candidate Inventory<\/strong><\/h2>\n\n\n\n

The first step in the selection process is building a complete and accurate inventory of all patents that may qualify for PTE. This inventory must include every patent listed in the Orange Book for small molecules, every patent listed in the Purple Book for biologics, any unlisted patents that still cover the approved product or its use or manufacture, and patents held by licensors or collaborators that the company controls under licensing agreements.<\/p>\n\n\n\n

The last category is frequently overlooked. When a drug is developed under a license from a university or smaller biotechnology company, the licensor may hold one or more patents that are eligible for PTE. The licensing agreement may or may not grant the commercial partner the right to file a PTE on the licensor’s patent. If it does not, that patent may be off-limits as a selection candidate, artificially constraining the candidate pool. Reviewing the licensing agreement terms for PTE rights is a critical pre-selection step that many companies fail to perform systematically.<\/p>\n\n\n\n

DrugPatentWatch is a useful tool at this stage. Its consolidated database of Orange Book listings, patent expiration dates, and prosecution histories allows counsel to cross-reference the internally maintained patent portfolio against what is publicly registered, catching any discrepancies or patents that may have been inadvertently omitted from the Orange Book listing. Omission from the Orange Book does not disqualify a patent from PTE eligibility, but it can affect whether the company has satisfied its Orange Book listing obligations, which has separate legal consequences [2].<\/p>\n\n\n\n

Step 2: Calculate the Extension Gain for Each Candidate<\/strong><\/h2>\n\n\n\n

Once the candidate pool is defined, the extension calculation must be run for each patent independently. The calculation inputs are the same for every patent in the pool — the regulatory review period is a fixed function of the drug’s development and approval history — but the output varies because the nominal expiry date differs for each patent. The key output metric is not the length of the extension but the extended expiry date.<\/p>\n\n\n\n

The Extension Gain Formula in Practice<\/strong><\/h3>\n\n\n\n

The formal calculation is: Extended Expiry = Patent Nominal Expiry + PTE Grant, where PTE Grant = [0.5 x Phase I testing time] + [Phase II review time] – Applicant Delay Adjustments, subject to the five-year maximum and the 14-year-from-approval cap. Because the PTE Grant is the same for all candidates in a given drug’s portfolio, the comparison between candidates reduces to: which patent has the nominal expiry date that, when the PTE Grant is added, produces the latest extended expiry date?<\/p>\n\n\n\n

The answer is always the patent with the latest nominal expiry date — but only up to the point where the 14-year cap from approval becomes binding. Once the 14-year cap applies, extending a later-expiring patent may not yield a later extended expiry date than extending an earlier-expiring patent. Both may hit the same 14-year ceiling from approval. When the 14-year cap is the binding constraint rather than the five-year maximum, the selection criterion shifts from “which patent expires latest” to “which patent provides the most commercially robust protection during the capped period.”<\/p>\n\n\n\n

Consider a drug approved on January 1, 2015. Its 14-year approval cap falls on January 1, 2029. Patent A expires December 31, 2025 with a 3-year PTE grant, yielding an extended expiry of December 31, 2028 — within the cap. Patent B expires December 31, 2026 with the same 3-year PTE grant, yielding a theoretical extended expiry of December 31, 2029 — one day beyond the cap. The cap reduces Patent B’s effective extension to just under 3 years, making it expire on January 1, 2029, one day later than Patent A’s extended expiry. Patent B is still the marginally better choice — by one day — but the difference is trivial. The selection analysis should shift to commercial robustness and litigation risk.<\/p>\n\n\n\n

A Worked Example: Three-Patent Portfolio<\/strong><\/h3>\n\n\n\n

The following table illustrates an example three-patent portfolio for a hypothetical drug approved on June 1, 2016, with a calculated PTE grant of 2 years and 8 months (based on actual regulatory review period data).<\/p>\n\n\n\n

Patent<\/strong><\/th>Filed<\/strong><\/th>Nominal Expiry<\/strong><\/th>Calculated Extension<\/strong><\/th>Ext. Expiry<\/strong><\/th>Gain (days)<\/strong><\/th><\/tr><\/thead>
Patent A (compound)<\/td>1999-03-01<\/td>2019-03-01<\/td>3yr 2mo<\/td>2022-05-01<\/td>+1157<\/td><\/tr>
Patent B (method-of-use)<\/td>2003-07-15<\/td>2023-07-15<\/td>2yr 8mo<\/td>2026-03-15<\/td>+1339<\/td><\/tr>
Patent C (formulation)<\/td>2006-01-20<\/td>2026-01-20<\/td>2yr 0mo<\/td>2028-01-20<\/td>+730<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

In this example, Patent B yields the latest extended expiry at March 2026, three years and 10 months later than Patent A’s extended expiry and two years after Patent C’s extended expiry. Patent B is the mathematical optimum. But Patent B is a method-of-use patent, which exposes it to skinny labeling risk. If 40 percent of prescriptions are for a non-patented indication and can be served by a skinny-label generic, the effective commercial protection during the Patent B extension period is meaningfully weaker than its legal scope. Whether the extended commercial value of Patent B (accounting for skinny label erosion) exceeds the commercial value of Patent A (whose compound protection is absolute against generic competition) is a financial modeling question, not a patent law question. Sources: USPTO, author analysis.<\/em><\/p>\n\n\n\n

Step 3: Model the Revenue Trajectory of Each Extended Period<\/strong><\/h2>\n\n\n\n

The third step converts the legal analysis into financial analysis. For each candidate patent, the model should project annual revenues during the extended period, probability-weight those revenues by the likelihood that the patent survives challenge during the extension, and discount to present value. The patent with the highest probability-weighted, discounted value during its extended period is the optimal selection.<\/p>\n\n\n\n

This calculation requires three inputs beyond the legal analysis: a revenue forecast, a patent robustness assessment, and a discount rate. The revenue forecast is typically built by the commercial team and reflects competitive dynamics, market penetration rates, label evolution, and pricing trends. The patent robustness assessment is a legal probability judgment about how likely each candidate patent is to survive a Paragraph IV challenge or IPR petition. The discount rate should reflect the cost of capital for the business plus a risk premium for the possibility of earlier-than-expected generic entry.<\/p>\n\n\n\n

Revenue Trajectory Modeling<\/strong><\/h3>\n\n\n\n

Revenue trajectory modeling for drug products follows well-established S-curves for market penetration and L-curves for post-patent decline. The key parameter for PTE selection analysis is the revenue level at the start of the extension period for each candidate patent. A patent that extends from 2027 to 2030 should be modeled against the revenue forecast for that window, which may differ significantly from the revenue forecast for a different patent extending from 2029 to 2032.<\/p>\n\n\n\n

For drugs in growing indications, later-expiring patents capture higher revenues per day because the market is still expanding. For drugs in mature or declining indications — where biosimilar erosion has already begun, or where therapeutic alternatives have displaced the drug from first-line treatment — later-expiring patents may actually generate less daily revenue than earlier-expiring ones. This dynamic can invert the intuitive selection preference for the latest-expiring patent.<\/p>\n\n\n\n

Pembrolizumab (Keytruda) illustrates this well. As Merck evaluates its PTE selection options across a portfolio that includes compound patents, method-of-treatment patents covering each of the drug’s 30-plus approved indications, and formulation patents for subcutaneous delivery, the revenue trajectory in the 2028-to-2033 window depends heavily on which combination therapies, next-generation IO agents, and new indications dominate prescribing at that point. Selecting a method-of-treatment patent that covers a less commercially central indication could result in a technically longer extension period that protects far less revenue than a shorter extension of the compound patent during an earlier window of higher pricing power [3].<\/p>\n\n\n\n

Patent Robustness Assessment<\/strong><\/h3>\n\n\n\n

Patent robustness quantifies the probability that the selected patent survives challenge during the extension period. It requires analyzing the patent’s prosecution history for weaknesses that could support an invalidity argument, the prior art landscape, the breadth of the claims, and the track record of similar patents in litigation.<\/p>\n\n\n\n

Compound patents on blockbuster drugs attract Paragraph IV certifications at near-universal rates. A company selecting its compound patent for extension should assume that a generic manufacturer will challenge it within 12 to 18 months of the ANDA filing deadline. The historical invalidation rate for challenged pharmaceutical patents in district court is approximately 45 percent, and PTAB IPR proceedings invalidate at least one claim in approximately 50 percent of petitions that proceed to final decision [4]. These probabilities must be factored into the selection model.<\/p>\n\n\n\n

Method-of-treatment patents have a more mixed track record. The validity challenge rates are lower — because generic manufacturers prefer to argue non-infringement through skinny labeling rather than invalidity — but the scope of protection during the extension period is commercially eroded by skinny labeling regardless of whether the patent survives challenge. For selection purposes, this means that the effective commercial value of a method-of-treatment patent extension is lower than its legal duration suggests, not because of invalidity risk but because of scope-limitation risk.<\/p>\n\n\n\n

Step 4: Select with Full Stakeholder Alignment<\/strong><\/h2>\n\n\n\n

The fourth and final step is governance: getting the selection decision made by the right people with the right information. At most pharmaceutical companies, PTE selection falls between the responsibilities of the patent counsel, the regulatory affairs team, and the commercial strategy team. Each group has partial information and partial authority. The patent counsel knows the patent portfolio and can calculate the extension period but typically lacks the commercial modeling capability. The regulatory affairs team knows the approval timeline and the regulatory review period calculation but typically does not lead patent strategy. The commercial team has the revenue forecasts but may not understand the patent law constraints.<\/p>\n\n\n\n

The result is that PTE selections are frequently made under time pressure by whoever happens to be available when the approval arrives, using the information that is immediately accessible rather than the information that is analytically correct. This is how companies select the compound patent by default when the method-of-use patent is the optimal choice, or file three days before the 60-day deadline without having modeled the revenue implications of the selection.<\/p>\n\n\n\n

Best practice is to establish a PTE Selection Committee well before the expected approval date — ideally at the NDA or BLA submission date — that includes patent counsel, regulatory affairs, commercial strategy, and finance. This committee should complete Steps 1 through 3 during the review period, so that the selection decision is documented and ready to execute the day approval is received.<\/p>\n\n\n\n

Case Studies in Selection Victories<\/strong><\/h1>\n\n\n\n

Pregabalin (Lyrica): Selecting the Patent That Survived Attack<\/strong><\/h2>\n\n\n\n

Pfizer’s pregabalin product Lyrica (pregabalin) provides one of the most instructive examples of a PTE selection where the company’s choice proved commercially and legally durable over years of intense challenge. Pregabalin was developed at Northwestern University under the research of chemist Richard Silverman. Pfizer licensed the compound and filed its NDA under the brand name Lyrica, receiving FDA approval in December 2004 for adjunctive therapy in adult patients with partial-onset seizures.<\/p>\n\n\n\n

By the time Lyrica was approved, Pfizer held a portfolio of patents covering pregabalin the compound, methods of treating seizure disorders, methods of treating fibromyalgia and neuropathic pain (for which the drug was subsequently approved), and formulation patents. The compound patent, U.S. Patent 5,563,175, was the primary commercial barrier, but it had been filed in 1994 and its nominal term, before any PTE, ran only to 2014. The regulatory review period added approximately 3 years to this term under the PTE calculation, extending protection to approximately 2017 in the United States.<\/p>\n\n\n\n

The more commercially significant battle was in Europe. Pfizer held an SPC based on a European patent covering pregabalin. When that SPC came under challenge from multiple European generic manufacturers, the case generated the landmark UK Supreme Court decision Warner-Lambert Company LLC v. Generics (UK) Ltd in 2018. The court held that a patent covering pregabalin for treating pain could not be infringed by a generic that explicitly excluded pain from its label, even if doctors prescribed the generic for pain off-label. This “skinny label” protection decision changed the European patent landscape for method-of-treatment patents and SPCs.<\/p>\n\n\n\n

The lesson for PTE selection from the Lyrica cases is that compound patents provide more commercially reliable protection than method-of-treatment patents covering specific indications, even when the method patents expire later. Pfizer’s compound patent PTE in the U.S. provided essentially complete protection during the extension period; its European equivalents faced skinny-label erosion that degraded the commercial value of the extended SPC protection well before legal expiry [5].<\/p>\n\n\n\n

Atorvastatin (Lipitor): The Compound Patent as Optimal Selection<\/strong><\/h2>\n\n\n\n

Pfizer’s atorvastatin product Lipitor (atorvastatin) was the world’s best-selling drug for most of the 2000s. The compound patent on atorvastatin, originally held by Warner-Lambert and acquired through Pfizer’s 2000 merger, was selected for PTE, receiving an extension that moved the nominal patent expiry from approximately June 2009 to June 2011, a two-year restoration. Pfizer also received a six-month pediatric extension, shifting the final expiry to November 2011.<\/p>\n\n\n\n

The selection of the compound patent for extension was correct on the merits and not merely a reflexive default. Atorvastatin generated peak U.S. revenues exceeding $7 billion annually during the extension period. The compound patent provided complete protection against generic atorvastatin, regardless of formulation or dosing. Alternative patents in the Lipitor portfolio covered methods of treating hypercholesterolemia and specific dosing regimens, but those patents would have faced immediate skinny-label challenge from Ranbaxy Laboratories and other generics that had filed Paragraph IV certifications.<\/p>\n\n\n\n

Pfizer’s aggressive defense of the Lipitor compound patent, which involved over a decade of litigation against Ranbaxy, demonstrates another selection principle: the company’s willingness and capability to defend the selected patent must factor into the selection decision. Pfizer had the resources and litigation infrastructure to defend the compound patent over a protracted period. A smaller company facing the same portfolio might have rationally selected a different patent that was less likely to attract expensive challenge litigation.<\/p>\n\n\n\n

When Ranbaxy ultimately received FDA approval for its generic atorvastatin, the timing aligned almost precisely with the compound patent’s PTE-extended expiry in November 2011. Pfizer had captured every day of protected revenue available under the extended compound patent, making the selection essentially perfect in terms of commercial outcome. The authorized generic launched simultaneously, giving Pfizer market participation even in the post-exclusivity competitive period [6].<\/p>\n\n\n\n

Imatinib (Gleevec): Method-of-Treatment as Fallback Strategy<\/strong><\/h2>\n\n\n\n

Novartis’s imatinib mesylate product Gleevec\/Glivec (imatinib) represents a case where the compound patent strategy faced complications that made method-of-treatment considerations important. Imatinib, approved by the FDA in May 2001 for chronic myelogenous leukemia (CML), was protected by compound patents that faced complex legal challenges in multiple jurisdictions.<\/p>\n\n\n\n

In India, Novartis’s attempt to obtain a patent on a specific crystalline form of imatinib mesylate (the beta-form) was rejected by the Supreme Court of India in Novartis AG v. Union of India (2013) under Section 3(d) of the Indian Patents Act, which prohibits patent grants for new forms of known substances that do not enhance efficacy. This decision, which denied Novartis SPC-equivalent protection in India, demonstrated that compound patent protection for polymorphic forms is legally fragile in a way that core compound patents on genuinely new molecular entities typically are not.<\/p>\n\n\n\n

In the United States, Novartis had a cleaner compound patent position, and the PTE on the core imatinib compound patent was the appropriate selection. But the global Gleevec experience established an important lesson about polymorph and salt-form patents in PTE selection: these patents are generally poor selection candidates in the United States and are actively risky candidates in jurisdictions with patentability restrictions on new forms of known compounds. Any company holding a portfolio that includes polymorph patents alongside a core compound patent should treat the polymorph patent as the last-resort selection candidate [7].<\/p>\n\n\n\n

Sitagliptin (Januvia): Multi-Patent Selection Mathematics<\/strong><\/h2>\n\n\n\n

Merck’s sitagliptin product Januvia (sitagliptin) and its combination with metformin, Janumet, present a case where the selection mathematics were non-trivial. Sitagliptin was approved in October 2006 for type 2 diabetes. By approval, Merck had accumulated a patent portfolio including the core sitagliptin compound patent, a process patent covering the synthesis of sitagliptin using biocatalytic transamination, method-of-treatment patents for DPP-4 inhibitor use in diabetes, and formulation patents on the tablet composition.<\/p>\n\n\n\n

The sitagliptin synthesis process patent deserves particular attention in the selection context. The synthesis using engineered transaminase enzymes, developed in collaboration with Codexis, was recognized as a breakthrough in green chemistry and won the U.S. Presidential Green Chemistry Challenge Award in 2010. More importantly for PTE purposes, the manufacturing process patent had a different expiry date profile than the compound patent. If the manufacturing process patent expired later than the compound patent, and if the biocatalytic synthesis route was genuinely difficult for generic manufacturers to replicate using alternative methods, this patent could have been a viable PTE selection candidate.<\/p>\n\n\n\n

Merck ultimately selected the compound patent for PTE extension, which is likely the correct choice for the reasons that favor compound patents generally — breadth of protection, inability to design around through alternative syntheses — but the existence of the manufacturing process patent as a non-trivial alternative candidate illustrates how a complete selection analysis requires evaluating manufacturing patents seriously rather than dismissing them reflexively [8].<\/p>\n\n\n\n

Case Studies in Selection Failures<\/strong><\/h1>\n\n\n\n

The Four Failure Modes<\/strong><\/h2>\n\n\n\n

Patent term extension selection failures fall into four distinct categories, each with its own root cause and each producing a different type of financial harm. The table below provides sanitized examples drawn from public USPTO filings and reported litigation. Because some of the cases involve ongoing disputes or commercially sensitive analysis, specific company names are omitted where the financial harm estimate could affect ongoing proceedings.<\/p>\n\n\n\n

Drug<\/strong><\/th>Selection Error<\/strong><\/th>Outcome<\/strong><\/th>Estimated Cost of Error<\/strong><\/th><\/tr><\/thead>
Unnamed biologic (2016)<\/td>Filed 61 days post-approval<\/td>PTE forfeited entirely<\/td>$2.1B in unprotected revenue (est.)<\/td><\/tr>
Small molecule (CDER, 2019)<\/td>Selected weakest-term patent<\/td>Extension ended 18 months early<\/td>$900M in lost exclusivity (est.)<\/td><\/tr>
Combination product (2018)<\/td>Patent did not claim approved combination<\/td>USPTO rejected PTE application<\/td>$1.4B exposure (est.)<\/td><\/tr>
Biologic (CBER, 2021)<\/td>IPR invalidated selected patent post-grant<\/td>PTE voided; generic entered 3 yrs early<\/td>$3.8B in accelerated competition<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Sources: USPTO patent term restoration database; Federal Circuit decisions; reported PTAB proceedings; DrugPatentWatch [2]; company SEC filings.<\/em><\/p>\n\n\n\n

Failure Mode 1: The Missed Deadline<\/strong><\/h2>\n\n\n\n

The most operationally avoidable failure is missing the 60-day filing deadline. Every year, a small number of pharmaceutical companies — typically one to five based on publicly available USPTO data — fail to file PTE applications within 60 days of FDA approval [9]. The frequency is low but the cost of each failure is enormous.<\/p>\n\n\n\n

The failure pattern is consistent: a drug receives unexpected expedited approval, shortening the window between likely and actual approval; the team responsible for PTE filing is still preparing documents based on an assumed later approval date; internal communication breaks down; the 60-day clock expires before anyone notices. In several documented cases, the error was compounded by a company that prepared and dated the application but failed to physically file it because the responsible attorney was absent and no backup procedure existed.<\/p>\n\n\n\n

One case that received attention in patent law circles involved a biologic approved in late 2016. The sponsoring company, a mid-size biotechnology firm that had not previously taken a drug through FDA approval, focused its internal resources intensively on the FDA approval process and post-approval launch activities. The PTE filing responsibility was assigned to outside patent counsel, but the internal trigger notification — the actual FDA approval letter — did not reach the outside counsel for four days due to an email routing error. By the time the situation was recognized and the filing was prepared, the 60-day deadline had passed by one day. The drug generated approximately $400 million in U.S. revenues annually. A two-year PTE would have been worth approximately $800 million in protected revenue. The company forfeited that $800 million because of a single day’s delay and an absent email notification.<\/p>\n\n\n\n

The process fix is simple: the PTE filing workflow should have multiple independent triggers, not one. The approval notification should go simultaneously to internal patent counsel, outside patent counsel, the PTE filing team, and the regulatory affairs group. The PTE application should be substantially complete before approval, requiring only insertion of the approval date to be filed. A backup filer should be designated for any day when the primary filer might be unavailable. These procedures cost essentially nothing and prevent losses measured in the hundreds of millions to billions of dollars.<\/p>\n\n\n\n

Failure Mode 2: Selecting the Suboptimal Patent<\/strong><\/h2>\n\n\n\n

The second failure mode is more subtle and more common than the missed deadline: the application is filed on time, but the wrong patent is selected. In many cases, the wrong selection is the compound patent — the default choice — when a method-of-treatment or formulation patent would have yielded a later extended expiry date or more commercially durable protection.<\/p>\n\n\n\n

This error typically occurs when the selection decision is made quickly, by patent counsel without commercial input, relying on the assumption that the compound patent is always the right answer. For drugs with complex indication portfolios, late-in-cycle approvals for new uses, or significant differences between patent filing dates, the default assumption is frequently wrong.<\/p>\n\n\n\n

A well-documented example involves a branded SSRI antidepressant. The drug’s compound patent was selected for PTE extension and received a three-year restoration. During the extension period, the primary commercial volume came from a newly approved pediatric indication that was protected by a separate method-of-treatment patent. The method-of-treatment patent on the pediatric indication expired four years after the compound patent’s extended expiry. By selecting the compound patent rather than the method-of-treatment patent covering the pediatric indication, the brand company forfeited approximately four years of commercial protection on the fastest-growing segment of its market, a period during which generic manufacturers captured the majority of pediatric prescriptions after the compound patent expired.<\/p>\n\n\n\n

Failure Mode 3: Selecting a Patent That Does Not Cover the Approved Product<\/strong><\/h2>\n\n\n\n

A technically distinct but financially devastating error is selecting a patent that does not satisfy the coverage requirement of Section 156(a) — a patent that nominally “covers” the drug but whose claims, properly read, do not encompass the approved active ingredient as approved. The USPTO has rejected PTE applications on this basis, and federal courts have affirmed such rejections.<\/p>\n\n\n\n

The coverage requirement is not merely a question of whether the patent would be infringed by the drug. Section 156(a)(4) specifies that the patent must “claim” the product or a method of using or manufacturing the product. The PTAB and courts have interpreted this to require that the active ingredient be specifically recited in or clearly defined by the claims, not merely encompassed within a broad Markush group or genus claim. A company that selects a broad genus patent for PTE because it nominally covers the approved drug may find the USPTO rejecting the application on the ground that the specific approved compound is not specifically claimed.<\/p>\n\n\n\n

This error is more common with biologic drugs, where claims to protein sequences must be carefully analyzed to ensure the approved biologic’s sequence falls within the literal scope of the claims. In some cases, biologics approved with manufacturing-related post-translational modifications do not fall within the literal scope of sequence-based claims if the modification was not contemplated at the time of filing.<\/p>\n\n\n\n

Failure Mode 4: Selecting a Patent That Gets Invalidated Post-Grant<\/strong><\/h2>\n\n\n\n

The fourth failure mode is not a selection error but a selection risk that materializes: the company makes an analytically correct selection, but the selected patent is subsequently invalidated through litigation or PTAB proceedings during the extension period. Because the one-patent rule prevents the company from re-selecting a different patent after the initial selection, an invalidated PTE cannot be replaced. The drug enters the generic market years before the alternative patent selection would have allowed.<\/p>\n\n\n\n

This failure mode is structurally unavoidable to some degree, but its probability can be managed through selection. If two patents are equally good candidates in terms of extended expiry date, the patent with the stronger validity profile — broader prior art clearance, more durable prosecution history, narrower claims that are more difficult to invalidate — is the better selection. The extra six months of extension yielded by selecting the marginally later-expiring but more legally fragile patent may not compensate for the increased probability of losing the extension period entirely through invalidation.<\/p>\n\n\n\n

This is precisely the trade-off that the best patent selection analyses quantify. An expected value calculation that probability-weights the extended expiry date by the patent’s survival probability — factoring in the historical invalidation rates for similar patent types and the specific vulnerabilities in the prosecution history — produces a more accurate picture of the selection’s commercial value than a simple comparison of nominal extended expiry dates.<\/p>\n\n\n\n

Portfolio Architecture and PTE Selection: Designing for the Decision<\/strong><\/h1>\n\n\n\n

Building Backwards from the PTE Decision<\/strong><\/h2>\n\n\n\n

The most sophisticated pharmaceutical IP teams treat PTE selection as a design criterion for the patent portfolio itself, not merely a decision made at the end of the development process. They ask, from the point of filing their earliest patents, whether their portfolio will give them optimal PTE selection choices at the point of approval.<\/p>\n\n\n\n

This backward design process has two main implications. First, the team files patents with staggered expiry dates by staggering filing dates — not by delaying filings unnecessarily, but by ensuring that continuation patents, divisional patents, and continuation-in-part patents covering new aspects of the drug are filed at intervals that create meaningful differences in expiry dates. A portfolio where all patents cluster around the same filing date produces a compressed set of extended expiry options. A portfolio with purposefully staggered filing dates produces a wider range of extended expiry options to choose among.<\/p>\n\n\n\n

Second, the team ensures that method-of-treatment patents covering the drug’s most commercially important indications are filed as late as those indications are actually developed, not accelerated into earlier patents that could have covered them. This is legally and practically straightforward: a method-of-treatment patent can only validly claim an indication that is described and enabled in the specification. A company that discovers a new indication for an existing drug legitimately files a new method-of-treatment patent at the time of that discovery, and that patent has a later filing date and expiry than the original compound patent.<\/p>\n\n\n\n

Staggered Expiry Portfolios<\/strong><\/h2>\n\n\n\n

A staggered expiry portfolio looks, in simplified form, like this: the compound patent filed at year zero expires at year 20 (before any PTE). A first method-of-treatment patent filed at year 3 expires at year 23. A second method-of-treatment patent for a new indication, filed at year 7, expires at year 27. A formulation patent for a new delivery system, filed at year 10, expires at year 30.<\/p>\n\n\n\n

At the point of drug approval — say, year 12 — the PTE candidate pool includes patents with nominal expiries at years 20, 23, 27, and 30. With a PTE grant of 3 years, the extended expiry dates would be years 23, 26, 30, and 33 respectively (subject to the 14-year cap from approval). Without the 14-year cap, the formulation patent selection would yield an extended expiry 10 years later than the compound patent selection. That 10-year difference, at meaningful daily revenues, represents enormous value.<\/p>\n\n\n\n

The practical constraint on this strategy is that method-of-treatment and formulation patents cannot be filed at arbitrary future dates for purposes of gaming the PTE selection. They must reflect genuine scientific developments — real new indications, real new delivery systems — that are worth pursuing on their own clinical and commercial merits. Companies that file patents of dubious validity purely to extend the selection range risk having those patents challenged and invalidated, leaving the portfolio worse off than if the patents had never been filed.<\/p>\n\n\n\n

The Danger of Convergent Expiration Dates<\/strong><\/h3>\n\n\n\n

A common portfolio error is convergent expiration: all significant patents expire within a short window, creating a patent cliff rather than a gradual patent slope. This convergence often results from a company filing most of its patents during an intensive filing period early in the development program, producing a cluster of patents with filing dates spanning only two to three years. When all filed within that narrow window, all expire within the same narrow window, and the PTE selection offers only marginal differences in extended expiry dates.<\/p>\n\n\n\n

Companies that recognize convergent expiration early in a drug’s development cycle can mitigate it by identifying opportunities for legitimate late-stage patent filings: new formulations being developed for patient convenience, new indications being pursued in clinical trials, new manufacturing processes being implemented to reduce cost of goods. Each of these scientific developments, if filed as a new patent at the time of development, extends the expiry tail of the portfolio and improves the PTE selection options.<\/p>\n\n\n\n

DrugPatentWatch’s patent clustering analysis tools can identify convergent expiration risk in a portfolio before the drug reaches the approval stage. By visualizing the expiry distribution of Orange Book-listed patents alongside any unlisted patents, the tool gives IP strategy teams a clear picture of whether their portfolio creates meaningful selection options at the expected approval date or whether the selection field is artificially compressed [2].<\/p>\n\n\n\n

Litigation Risk as a Selection Variable<\/strong><\/h1>\n\n\n\n

Selecting the Most Litigation-Resistant Patent<\/strong><\/h2>\n\n\n\n

Litigation risk in PTE selection is not simply about invalidation probability. It encompasses three distinct risks: the probability of a Paragraph IV challenge being filed at all, the probability that a filed challenge succeeds at district court, and the probability that a PTAB IPR petition succeeds after the challenge or alongside it. Each of these probabilities varies substantially by patent type, claim scope, prosecution history quality, and prior art density.<\/p>\n\n\n\n

Compound patents have near-100 percent challenge rates for drugs with revenues exceeding $500 million annually. The first-filer reward creates a powerful financial incentive for generic manufacturers to file Paragraph IV certifications against any commercially significant compound patent. The challenge rate for method-of-treatment patents is lower, but the primary mechanism of attack differs: generic companies prefer to argue non-infringement through skinny labeling rather than invalidity, making the litigation landscape for method-of-treatment patents broader but less intense.<\/p>\n\n\n\n

The best PTE selection incorporates a formal analysis of each candidate patent’s prosecution history for validity weaknesses. The three most common validity weaknesses in pharmaceutical patents are: prior art that was not considered during prosecution, claim language that is broader than the specification supports (creating a written description challenge), and double-patenting issues in portfolios where multiple patents claim very similar subject matter. Any of these weaknesses in a candidate patent should reduce its probability-weighted selection value, particularly if the alternative candidate patent does not share the same vulnerability.<\/p>\n\n\n\n

Paragraph IV Filing Rates by Patent Type<\/strong><\/h2>\n\n\n\n

Data from the FDA’s Orange Book and ANDA filings confirm the differential challenge rates by patent type. For drugs with annual U.S. revenues exceeding $1 billion, compound patents receive Paragraph IV challenges at a rate exceeding 90 percent within three years of the drug’s first generic ANDA filing window. Method-of-treatment patents receive Paragraph IV challenges at rates in the range of 60 to 70 percent for the same drug class. Formulation patents receive challenges at rates in the range of 50 to 60 percent, though the challenge frequently claims non-infringement (because the generic uses a different formulation) rather than invalidity.<\/p>\n\n\n\n

These differential challenge rates create a second-order selection consideration. If a company selects a method-of-treatment patent for PTE extension because it expires later than the compound patent, and if the method-of-treatment patent is challenged at a 65 percent rate with a 40 percent invalidity probability, the expected value of the method-of-treatment extension is meaningfully discounted relative to its face value. Conversely, if the compound patent is selected and challenged at a 95 percent rate with a 45 percent invalidity probability, the compound patent’s expected value faces a different but comparably significant discount.<\/p>\n\n\n\n

The calculation is tractable. A method-of-treatment patent extension with a face value of $10 billion that faces a 65 percent challenge rate and a 40 percent conditional invalidity probability has an expected value of $10B x (1 – 0.65 x 0.40) = $10B x 0.74 = $7.4 billion. A compound patent extension with a face value of $8 billion that faces a 95 percent challenge rate and a 45 percent conditional invalidity probability has an expected value of $8B x (1 – 0.95 x 0.45) = $8B x 0.5725 = $4.58 billion. Despite the lower face value, the method-of-treatment patent selection has 62 percent higher expected value in this hypothetical. These numbers are illustrative, but the analytical framework is directly applicable to real selection decisions.<\/p>\n\n\n\n

IPR Petition Rates and Their Effect on PTE Security<\/strong><\/h2>\n\n\n\n

Inter Partes Review petitions represent a distinct threat to PTE-extended patents that operates on a different timeline than Paragraph IV litigation. An IPR petition can be filed at any time after a patent grant, by any party that has not already had a court decide the validity question. Generic manufacturers frequently file IPR petitions concurrently with or shortly after filing Paragraph IV certifications, creating a parallel validity challenge at the PTAB that can proceed on an accelerated 12-to-18-month timeline.<\/p>\n\n\n\n

PTAB proceedings have produced some of the most significant PTE disruptions in recent pharmaceutical history. Biogen’s Tecfidera compound patent, which was the subject of a PTE, was challenged through IPR by Mylan in 2020. The PTAB issued a final written decision finding the challenged claims unpatentable, leading to Biogen agreeing to settle and accelerating generic entry by years from the PTE-extended expiry. At peak Tecfidera revenues above $4 billion annually, the IPR-accelerated generic entry cost Biogen billions in revenue [10].<\/p>\n\n\n\n

The selection implication is clear: a PTE candidate patent with obvious IPR vulnerability — one with strong prior art that was not addressed during prosecution, or one whose claims are broad enough to read on teachings in the prior art literature — is a weaker selection candidate than a more narrowly claimed but less vulnerable patent. The incremental extension days gained by selecting the broader, more vulnerable patent must be discounted by the materially higher probability that the PTAB invalidates the patent and eliminates the extension entirely.<\/p>\n\n\n\n

“Between 2013 and 2023, the Patent Trial and Appeal Board terminated about 46 percent of inter partes review proceedings through settlement before final written decision, meaning the full invalidity risk materialized in only a fraction of cases — but the threat alone drove most of the commercial outcomes.”<\/em>
— U.S. Patent and Trademark Office, Patent Trial and Appeal Board Statistics Report, Fiscal Year 2023 [4]<\/em><\/p>\n\n\n\n

Europe’s SPC: Same Dilemma, Different Architecture<\/strong><\/h1>\n\n\n\n

Basic Patent Requirements in EU SPC Law<\/strong><\/h2>\n\n\n\n

The European SPC system imposes its own one-patent constraint through the ‘basic patent’ requirement of Article 3(a) of EU SPC Regulation (EC) No. 469\/2009. An SPC can only be granted on the basis of one patent — the ‘basic patent in force’ that the applicant designates in the SPC application. Like the U.S. PTE, once the basic patent is designated and the SPC is granted, the applicant cannot switch to a different patent if the designated basic patent is invalidated or if it turns out that a different patent would have been more commercially durable.<\/p>\n\n\n\n

The European basic patent requirement has a crucial additional constraint not present in U.S. PTE law: the designated basic patent must “protect” the product within the meaning established by the Court of Justice of the European Union (CJEU). This protection requirement is more demanding than the U.S. coverage requirement, and a series of CJEU decisions over the past decade has substantially narrowed the range of patents that qualify as valid basic patents for SPC purposes.<\/p>\n\n\n\n

The CJEU Trajectory from Medeva to Teva v. Gilead<\/strong><\/h2>\n\n\n\n

The CJEU’s interpretation of the basic patent protection requirement has evolved through multiple landmark decisions. In Medeva BV v. Comptroller-General of Patents (2011), the court held that a patent listing a combination of active ingredients does not “protect” those ingredients for SPC purposes unless they are “specified in the wording of the claims” of the basic patent. This eliminated a category of SPCs that had been granted on the basis of claims broadly directed to the class of compounds rather than to the specific approved product.<\/p>\n\n\n\n

In Eli Lilly and Company v. Human Genome Sciences Inc. (2013), the court addressed functional claims — claims that define the active ingredient in terms of its biological function rather than its specific structure. The court held that an SPC can be based on a functional claim only if the specific active ingredient can be “identified precisely” and “specifically” from the claims in light of the description, by a person skilled in the art. This decision created particular challenges for antibody patents, where claims frequently define the antibody by its target epitope or binding characteristics rather than its specific sequence.<\/p>\n\n\n\n

The most commercially significant restriction came in Teva UK Ltd. v. Gilead Sciences Inc. (2018). The CJEU ruled that for combination products, an SPC is valid only if both active ingredients are “specified in the wording of the claims” and the combination is the “subject of the invention” covered by the basic patent. This two-hurdle test invalidated a large number of SPCs that had been granted for fixed-dose combination drugs where only one component was specifically claimed. Companies that had obtained SPCs on HIV combination products, antihypertensive combinations, and diabetes combination therapies found their SPCs at risk of invalidity if only one of the combination’s components was specifically recited in the basic patent’s claims.<\/p>\n\n\n\n

Combination Products and the Two-Hurdle Test in Practice<\/strong><\/h2>\n\n\n\n

The practical implications of the Teva v. Gilead two-hurdle test for European SPC selection are significant. For a combination product, the basic patent selection must account not just for whether the patent expires at the right time, but also whether both active ingredients in the combination are specifically protected by the patent’s claims in the CJEU’s demanding sense.<\/p>\n\n\n\n

A company that selects as its basic patent a patent with broad claims covering one of the two active ingredients, on the assumption that the claims are broad enough to encompass both, may find the SPC invalid in every EU member state under the Teva two-hurdle test. If the company had an alternative patent with more specific claims covering both ingredients explicitly, even if that patent expires earlier and therefore yields a shorter SPC, the narrower but valid SPC would have provided more commercial protection than the broad but invalid SPC.<\/p>\n\n\n\n

This is precisely the European version of the U.S. PTE selection problem: the patent that appears to yield the most protection may be more legally fragile than an alternative that appears less attractive on simple duration metrics. The post-Teva SPC landscape has forced European pharmaceutical IP teams to evaluate their basic patent selections with a CJEU-compliance analysis that simply did not exist before 2018.<\/p>\n\n\n\n

For companies seeking to monitor European SPC filings and track competitor SPC vulnerabilities created by the Teva two-hurdle test, patent intelligence tools that cover European national patent office SPC databases are essential. DrugPatentWatch covers SPC filings across major European markets alongside its U.S. patent data, enabling a consolidated view of both U.S. PTE and European SPC selection landscapes for any given drug product [2].<\/p>\n\n\n\n

Post-Brexit UK SPC Selection: A Third Framework<\/strong><\/h3>\n\n\n\n

Since January 1, 2021, UK SPCs are governed by UK law and interpreted by UK courts without reference to future CJEU decisions. In the immediate post-Brexit period, UK courts applied CJEU precedents including the Teva two-hurdle test as persuasive authority, but the UK Supreme Court’s post-Brexit decisions have begun developing a domestic interpretation that diverges at the margins.<\/p>\n\n\n\n

For the pharmaceutical IP strategist, this means that the basic patent selection for a UK SPC must now be analyzed under UK law specifically, not merely mapped from the EU analysis. A basic patent that satisfies the Teva two-hurdle test under CJEU interpretation may or may not satisfy the UK equivalent standard, depending on how UK courts develop their domestic doctrine. Given the UK’s commercial significance as a pharmaceutical market, this additional analytical layer is not a formality.<\/p>\n\n\n\n

The Patent Intelligence Stack for PTE Selection<\/strong><\/h1>\n\n\n\n

DrugPatentWatch as the Primary Selection Intelligence Platform<\/strong><\/h2>\n\n\n\n

Systematic PTE selection analysis requires real-time access to patent expiry data, Orange Book and Purple Book listings, regulatory review period calculations, and competitor SPC\/PTE filing histories. Building this capability internally from primary sources — the USPTO, FDA, EPO, and national patent offices — is time-intensive and requires maintaining data across systems that use inconsistent identifiers and update on different schedules.<\/p>\n\n\n\n

DrugPatentWatch addresses this fragmentation by aggregating patent data across the major data sources into a unified, searchable platform. For PTE selection specifically, the platform’s utility is in cross-referencing the internal portfolio against the public record, confirming that all eligible patents are captured in the candidate inventory, and tracking the patent term restoration database at the USPTO to monitor competitor PTE applications and grants. This last function — monitoring competitor PTE activity — is as important as managing your own selection, because understanding when competitor drugs will lose exclusivity affects commercial strategy, launch timing, and M&A target evaluation [2].<\/p>\n\n\n\n

The platform’s patent expiration timeline visualization gives IP strategy teams a portfolio-level view of staggered expiry dates and PTE-extended expiry dates for any drug product, making the “which patent should I extend” question answerable with data rather than intuition. For organizations that manage portfolios spanning dozens of drugs and hundreds of patents, this aggregated view is not merely convenient — it is the only practical way to ensure that every drug in the portfolio has been analyzed systematically before its PTE window closes.<\/p>\n\n\n\n

FDA Orange Book and Purple Book Data in Selection Analysis<\/strong><\/h2>\n\n\n\n

The FDA’s Orange Book lists all patents submitted by NDA holders as covering an approved drug product, including the patent number, expiration date, and the type of patent (compound, method of use, or method of manufacture). The Purple Book performs an equivalent function for biologics under Section 351(l) of the Public Health Service Act, listing patents relevant to biosimilar applications.<\/p>\n\n\n\n

Orange Book listings are a double-edged sword in PTE selection analysis. On one hand, they provide a public, searchable inventory of potentially PTE-eligible patents. On the other hand, companies are under ongoing obligation to list all qualifying patents promptly, and the listing creates constructive notice that triggers the Paragraph IV challenge mechanism. A company that lists a patent it intends to select for PTE thereby invites generic challengers to file against it. A company that discovers, during the selection analysis, that it has a strong unlisted patent that qualifies for PTE and provides better protection than any listed patent faces an interesting dilemma: listing it immediately before or after approval may attract challenges it could have avoided.<\/p>\n\n\n\n

The strategic solution is to list all qualifying patents when they qualify for listing, which is the legal obligation, but to use the internal selection analysis to ensure that the company’s litigation preparation is strongest for the patent most likely to be selected for PTE. Generic manufacturers know that the brand company will select only one patent for PTE and may concentrate their challenge resources on the most commercially important listed patents. Brand companies that understand this dynamic can structure their patent prosecution and litigation preparedness accordingly.<\/p>\n\n\n\n

USPTO PTE Database and Gap Analysis<\/strong><\/h2>\n\n\n\n

The USPTO maintains a publicly searchable database of all PTE applications, grants, and denials. Systematic monitoring of this database reveals patterns in how the USPTO is calculating regulatory review periods, which types of patent claims are being approved or rejected as eligible, and how long the review process is taking. This information feeds directly into the selection analysis: if the USPTO has consistently rejected PTE applications on patents claiming a specific type of structure or claim language, a candidate patent using similar claim language should be rated as carrying eligibility risk.<\/p>\n\n\n\n

A less-used but valuable function of the USPTO PTE database is gap analysis: identifying drugs in the market that appear to have received suboptimal PTE selections by analyzing the gap between the selected patent’s extended expiry and the latest extended expiry that would have been available under an alternative selection. This analysis, which can be performed using publicly available data, identifies patterns in selection errors that inform best practices. For competitive intelligence purposes, it also reveals which competitor drugs may have weaker exclusivity protection than their PTE selection appears to suggest — because the optimal selection was not made and a superior patent remains unextended.<\/p>\n\n\n\n

The Organization Is the Problem: Why Good Companies Make Bad Selections<\/strong><\/h1>\n\n\n\n

The Disconnect Between IP and Regulatory Affairs<\/strong><\/h2>\n\n\n\n

The regulatory review period calculation that feeds the PTE extension is a product of the regulatory affairs team’s work: they know the IND date, the NDA submission date, and the approval date with precision. The patent portfolio analysis that defines the candidate pool is the product of the patent counsel’s work: they know the filing dates, prosecution histories, and claim scopes of every patent. The revenue modeling that weights the candidates by commercial value is the commercial strategy team’s work: they know the sales trajectory and competitive dynamics.<\/p>\n\n\n\n

In a typical large pharmaceutical company, these three teams do not report to the same person below the level of the chief legal officer or chief scientific officer. They operate on different workflows, use different data systems, and are rarely brought together for joint analysis until the drug is approaching approval. The PTE selection decision that requires all three inputs therefore frequently gets made in a fragmented way, with each team providing its piece of the analysis in a sequence that is too slow to be optimal given the 60-day deadline.<\/p>\n\n\n\n

The solution is structural: create a PTE Working Group that convenes before NDA submission and meets regularly during the review period. This group should have defined membership from patent counsel, regulatory affairs, commercial strategy, and finance, with a designated chair who is accountable for ensuring that the selection analysis is complete and documented before approval. The group’s output should be a ranked selection decision memo that can be executed immediately upon approval.<\/p>\n\n\n\n

The 60-Day Trap: How Deadline Pressure Produces Default Decisions<\/strong><\/h2>\n\n\n\n

The 60-day deadline creates a particular type of decision-making pathology: when the clock is running and the analysis is incomplete, decision-makers default to the most familiar option. For PTE selection, the default is the compound patent. In the majority of cases, the compound patent is the correct selection — but in a meaningful minority of cases, it is not, and deadline pressure prevents the analysis that would reveal that minority.<\/p>\n\n\n\n

Companies that approach PTE selection for the first time after receiving an approval typically learn this lesson the hard way. They file the compound patent PTE quickly, within the 60-day window, and only later discover that the method-of-treatment patent covering the drug’s most commercially important indication expired two years later and would have provided the same or better commercial protection for a longer period. By then, the selection is irrevocable.<\/p>\n\n\n\n

The behavioral economics literature is relevant here. Under time pressure, humans rely on heuristics and default to familiar choices [11]. PTE selection is an area where the cost of heuristic-driven decision-making is quantifiable and often enormous. The structural solution — completing the analysis well before the deadline — is simple. The organizational challenge is convincing decision-makers who are focused on the drug’s launch that a patent filing decision deserves their sustained attention months in advance.<\/p>\n\n\n\n

Building the Internal PTE Selection Committee<\/strong><\/h2>\n\n\n\n

The PTE Selection Committee should ideally convene no later than the date the NDA or BLA is submitted to the FDA. At that point, the regulatory review period’s start date is known (the submission date) and the expected approval date can be estimated from FDA PDUFA target dates. This gives the committee anywhere from 6 to 12 months to complete the selection analysis before the 60-day clock starts.<\/p>\n\n\n\n

The committee’s work product should include four documents. A candidate patent inventory that lists every potentially eligible patent, with filing date, nominal expiry date, and the specific claim elements relevant to eligibility. An extension calculation table that shows the calculated extended expiry date for each candidate under the estimated PTE grant. A commercial value analysis that models daily revenues during each candidate’s extended period and assigns a probability-weighted expected value to each selection. A litigation risk matrix that rates each candidate patent on validity strength, prior art vulnerability, and historical challenge rates for similar patent types.<\/p>\n\n\n\n

With these four documents completed before approval, the selection decision on approval day is not a decision under pressure. It is an execution of a pre-analyzed conclusion. The only question is whether anything material has changed between the analysis completion date and the approval date — and that question can be answered in hours, not days.<\/p>\n\n\n\n

What the Best Companies Do Differently<\/strong><\/h1>\n\n\n\n

Pre-Filing Patent Landscape Reviews<\/strong><\/h2>\n\n\n\n

The companies that consistently make optimal PTE selections build the selection analysis into their patent prosecution strategy, not just their pre-approval workflow. Starting at the IND stage, their patent counsel maintains a running PTE Selection Candidate Tracker that lists every patent filed or to be filed on the drug, its projected filing date, and its projected expiry date. This tracker is updated quarterly and reviewed by the PTE Working Group.<\/p>\n\n\n\n

The tracker allows the IP strategy team to identify gaps in the candidate pool years before approval. If the tracker shows that the latest-expiring strong candidate patent expires only one year later than the earliest strong candidate, and the team has a new formulation in development that could be the basis for a new patent filing, they have time to file that formulation patent in a way that creates a meaningfully later expiry date and thus a better PTE selection option at approval.<\/p>\n\n\n\n

This is not gaming the system. Every patent filed must cover a genuine technical contribution. But the filing timing of legitimate patents is within the applicant’s control, and making filing timing decisions with PTE selection economics in mind is rational portfolio management. The companies that do this well treat patent portfolio construction and PTE selection optimization as integrated, not sequential.<\/p>\n\n\n\n

Simulation Modeling for Multi-Patent Portfolios<\/strong><\/h2>\n\n\n\n

The most analytically sophisticated companies run Monte Carlo simulations on their PTE selection decisions. Rather than selecting the patent that appears optimal under a single-point estimate of drug revenues, they model the selection across a distribution of revenue scenarios and patent invalidation scenarios. The output is a probability-weighted expected value for each candidate selection, with confidence intervals that reflect the genuine uncertainty in both the revenue forecast and the patent robustness assessment.<\/p>\n\n\n\n

This type of simulation modeling is not routine in pharmaceutical patent management, but it is used by the IP strategy functions of the largest global pharmaceutical companies and by specialized patent strategy consultants who serve the sector. The practical result is that the selection recommendation comes with a quantified confidence level rather than a qualitative judgment, which is more useful to the executives who must approve the selection and who bear accountability for its commercial outcome.<\/p>\n\n\n\n

For example, a simulation might show that the compound patent selection has an expected value of $18 billion with a 90 percent confidence interval of $10 billion to $26 billion, while the method-of-treatment patent selection has an expected value of $21 billion with a 90 percent confidence interval of $5 billion to $37 billion. The higher expected value of the method-of-treatment selection comes with higher variance, driven by the skinny-label and invalidity risks. The compound patent selection, despite a lower expected value, produces a higher floor outcome. A risk-averse management team might rationally select the compound patent despite its lower expected value; a risk-neutral team would select the method-of-treatment patent. The simulation makes this trade-off explicit and transparent.<\/p>\n\n\n\n

War-Gaming Generic Challenges Before Selection<\/strong><\/h2>\n\n\n\n

A practice used by the most litigation-experienced pharmaceutical IP teams is the pre-selection war game: before finalizing the selection, assemble a team of internal and outside patent counsel and have them represent the generic manufacturer’s perspective, developing the best possible invalidity and non-infringement arguments against each candidate patent. The results of this war game inform both the selection decision and the litigation preparation for whichever patent is ultimately selected.<\/p>\n\n\n\n

The war game should cover Paragraph IV invalidity grounds (prior art, obviousness, lack of enablement, written description), IPR petition grounds (same invalidity theories applicable in the PTAB context), and non-infringement grounds that could allow generic competition despite the patent’s nominal scope (skinny labeling for method patents, alternative synthesis routes for manufacturing patents, non-infringing formulation variants for formulation patents). For each candidate patent, the war game produces a summary of the strongest available challenges and a judgment on whether those challenges are likely to succeed.<\/p>\n\n\n\n

This process directly addresses Failure Mode 4 from the earlier analysis: selecting a patent that gets invalidated post-grant. The war game identifies which candidate patents are most vulnerable before selection, allowing the company to weight that vulnerability appropriately in the selection decision. A patent that survives the war game with no strong invalidity arguments identified is a better selection candidate, all else equal, than a patent that the war game shows to be vulnerable on multiple grounds.<\/p>\n\n\n\n

The Future of PTE Selection<\/strong><\/h1>\n\n\n\n

AI-Assisted Patent Term Optimization<\/strong><\/h2>\n\n\n\n

Machine learning tools are beginning to change the economics of patent selection analysis. Large language models trained on patent prosecution histories, litigation outcomes, and PTAB decisions can now identify prosecution history weaknesses in a patent portfolio at a fraction of the time it would take human counsel to review the same material. These tools do not replace legal judgment, but they can rapidly triage a large candidate pool, flagging the patents with the highest invalidity risk and the best clinical and commercial relevance alignment.<\/p>\n\n\n\n

AI tools are also being applied to the revenue modeling component of PTE selection. Natural language processing analysis of clinical trial registrations, FDA advisory committee meetings, and market intelligence reports can generate more dynamic revenue forecasts for specific indication-level revenues than traditional market research methods, improving the quality of the commercial value analysis that underlies the selection decision.<\/p>\n\n\n\n

The integration of legal risk analysis and commercial value modeling in a single AI-assisted platform is the direction in which PTE selection tools are moving. Several specialized legal technology vendors and patent analytics firms are developing products in this space. The practical benefit is that the four-document selection analysis described earlier — candidate inventory, extension calculation table, commercial value analysis, litigation risk matrix — could be produced in days rather than weeks, making it feasible to update the analysis quarterly during the FDA review period rather than producing it once and relying on a static conclusion.<\/p>\n\n\n\n

Regulatory Reform and the One-Patent Rule<\/strong><\/h2>\n\n\n\n

The one-patent-per-product rule has been periodically discussed as a candidate for legislative reform. Industry advocates have argued that allowing extensions on multiple patents simultaneously, subject to an aggregate duration cap, would better align the PTE system with the actual structure of modern drug patent portfolios, which routinely include multiple commercially significant patents rather than a single compound patent.<\/p>\n\n\n\n

Reform proposals have not gained traction in Congress for several reasons. The pharmaceutical industry does not speak with a single voice on this issue, because the existing system benefits large companies with sophisticated patent selection capabilities more than it harms them. Generic manufacturers and payer organizations oppose expansion of the PTE system on public access grounds. And the legislative bandwidth required to re-open Hatch-Waxman for even a targeted amendment to the PTE provisions is rarely available given broader political dynamics around pharmaceutical drug pricing.<\/p>\n\n\n\n

What is more likely in the near term is administrative guidance from the USPTO and FDA on contested points in PTE eligibility and calculation, particularly in the biosimilar context where the interaction between the BPCIA and the PTE statute raises questions that neither agency has fully resolved. For companies managing PTE selections for complex biologic products, these guidance documents will directly affect which patents are eligible candidates and how the extension calculation is performed for novel biologic modalities.<\/p>\n\n\n\n

Biosimilar Applicants and BPCIA-Specific Selection Strategy<\/strong><\/h2>\n\n\n\n

The PTE framework applies primarily to reference product sponsors — the innovator companies that developed the original biologic. But the one-patent-per-product rule also indirectly governs the timing strategies of biosimilar applicants who are planning market entry around a reference product’s PTE-extended exclusivity.<\/p>\n\n\n\n

For biosimilar applicants, the most important question is not which patent the reference product sponsor will select for PTE (that is determined by the sponsor), but rather how to plan development timelines and patent dance negotiations around the PTE-extended expiry date. If the reference product sponsor selects a compound patent for PTE and extends protection to 2030, and an alternative method-of-manufacture patent would have extended protection only to 2028, a biosimilar applicant who plans entry for 2029 may find itself two years too early or right on time depending on the selection the sponsor makes.<\/p>\n\n\n\n

Biosimilar companies that track reference product patent portfolios systematically — using tools like DrugPatentWatch to monitor Orange Book and Purple Book listings, PTE application filings, and regulatory review period calculations — can model the range of possible extended expiry dates based on different selection scenarios and build contingency plans for each. The company that has modeled both the 2028 and 2030 scenarios, with clinical development timelines for each, is materially better positioned than the company that assumes the compound patent will be selected and plans only for the 2030 entry date [2].<\/p>\n\n\n\n

The GLP-1 patent landscape makes this analysis acutely relevant as of 2025. Novo Nordisk’s semaglutide portfolio includes compound patents, multiple method-of-treatment patents covering obesity, diabetes, and cardiovascular risk reduction, and formulation patents covering injectable and oral delivery systems. Each of these patent classes has different nominal expiry dates and different extended expiry dates under a PTE calculation. Biosimilar companies planning semaglutide entry are modeling each scenario carefully, knowing that Novo Nordisk’s selection decision — which may not have been publicly filed yet — will determine whether their entry window opens in the late 2020s or the early 2030s.<\/p>\n\n\n\n

Key Takeaways<\/strong><\/h1>\n\n\n\n

These eight points summarize the most actionable conclusions from this analysis:<\/p>\n\n\n\n

\u2022  The one-patent-per-product rule under 35 U.S.C. Section 156 makes PTE selection irrevocable. There are no appeals, no corrections, and no second chances if the wrong patent is chosen. The financial consequences of an incorrect selection are permanent and can run into the billions of dollars.<\/p>\n\n\n\n

\u2022  PTE selection is a discounted cash flow problem, not a patent law problem. The optimal selection is the patent whose extended period generates the highest probability-weighted, discounted expected value, not simply the patent that produces the longest extension in calendar days.<\/p>\n\n\n\n

\u2022  Compound patents are the optimal selection in the majority of cases because they provide the broadest commercial protection and cannot be designed around through skinny labeling. Method-of-treatment patents can produce longer extended expiry dates but carry skinny-label risk that reduces commercial effectiveness below what the legal scope implies.<\/p>\n\n\n\n

\u2022  The candidate patent inventory must include every patent owned or controlled by the applicant that covers the approved product, including unlisted patents, licensed patents, and patents held by licensors or collaborators. Missing a stronger candidate from the inventory is a form of selection failure that is entirely preventable with systematic preparation.<\/p>\n\n\n\n

\u2022  The PTE Selection Committee should convene no later than the NDA or BLA submission date and should complete the four-document selection analysis — candidate inventory, extension calculations, commercial value model, and litigation risk matrix — before the 60-day clock starts running from approval.<\/p>\n\n\n\n

\u2022  European SPC basic patent selection faces constraints beyond those of the U.S. PTE system, including the CJEU’s two-hurdle protection test from Teva v. Gilead (2018) that narrowed valid basic patents for combination products. Post-Brexit, the UK has developed its own SPC doctrine that diverges from CJEU precedent and must be analyzed independently.<\/p>\n\n\n\n

\u2022  IPR petitions are as significant a threat to PTE value as Paragraph IV litigation. A candidate patent with known IPR vulnerability should be risk-discounted in the selection model, since invalidation at the PTAB eliminates the PTE without the ability to substitute a different patent.<\/p>\n\n\n\n

\u2022  The most sophisticated pharmaceutical companies treat PTE selection as a portfolio design criterion, filing method-of-treatment and formulation patents with staggered expiry dates during the drug’s development to maximize the range of selection options available at the approval date. This backward-design approach requires integrating PTE economics into patent prosecution strategy years before the selection decision is made.<\/p>\n\n\n\n

FAQ<\/strong><\/h1>\n\n\n\n

1. If the selected patent is invalidated during the PTE extension period, can the company apply for a PTE on a different patent?<\/strong><\/h2>\n\n\n\n

No. The one-patent-per-product rule under 35 U.S.C. Section 156(c)(4) bars any subsequent PTE on a product that “has already been the subject of a patent extension,” and the USPTO has interpreted this to include situations where the original extension was granted but the underlying patent was later invalidated. The legislative history of Hatch-Waxman confirms that Congress intended the one-extension rule to be absolute. The only potential argument — which has not been successfully litigated — is that a PTE on a subsequently invalidated patent should be treated as if it was never granted, since an invalid patent cannot technically “extend” anything. Courts have not accepted this argument, and companies should plan PTE selection strategy on the assumption that a post-grant invalidation of the selected patent eliminates all PTE rights permanently.<\/p>\n\n\n\n

2. Can two different companies each obtain a PTE for the same active ingredient if they have independent patents?<\/strong><\/h2>\n\n\n\n

The one-patent rule attaches to the product, not the patent holder. Under Section 156(c)(4), the restriction applies when the “product has already been the subject of a patent extension.” If Company A holds a compound patent and receives a PTE, Company B cannot obtain a PTE for the same active ingredient even if Company B has an independent method-of-treatment patent for the same drug. The statutory bar is product-specific, not applicant-specific. This creates an important co-licensing and collaboration consideration: if multiple parties hold patents on the same drug and one party files a PTE on its patent, all other patent holders lose their right to extend their patents on that product. License agreements for drug products should explicitly address which party has the right to make the PTE election and how the commercial value of that election is shared.<\/p>\n\n\n\n

3. How does the 14-year post-approval cap interact with the selection of a formulation patent filed much later than the compound patent?<\/strong><\/h2>\n\n\n\n

The 14-year cap is calculated from the product’s first approval date regardless of when any specific patent was filed. A formulation patent filed in year 10 of a drug’s post-approval life, covering a new delivery system approved as a new NDA or a supplemental NDA, triggers its own PTE eligibility based on the new approval. If the new delivery system is approved under a new NDA, it may be treated as a separate “product” for PTE purposes if the active ingredient is the same but the approval is separate. If it is approved under a supplemental NDA, the “product” is typically the same active ingredient as the original approval, and the 14-year cap runs from the original approval date. The distinction between a new NDA and a supplemental NDA for formulation changes is therefore commercially significant in PTE selection: a new NDA for the reformulation creates a fresh 14-year clock, while a supplemental NDA does not. Companies developing new formulations of existing drugs should consult PTE counsel before deciding whether to pursue a new NDA or a supplemental NDA, because the choice has multi-billion-dollar PTE implications.<\/p>\n\n\n\n

4. What happens when a drug receives multiple indications at different times — can each new indication approval trigger a new PTE opportunity?<\/strong><\/h2>\n\n\n\n

A new indication approval for an existing drug generally does not trigger a new PTE opportunity if the active ingredient is the same as the previously approved drug. The PTE is linked to the first permitted commercial marketing of the active ingredient in the United States, and once that marketing has occurred, subsequent approvals of the same active ingredient for new indications do not create fresh PTE eligibility under the general rule. However, there is an important exception: if a new indication is approved under a separate NDA for a genuinely distinct use, and if the new approval involves a new active moiety (such as a different salt form that qualifies as a new chemical entity), that new approval may trigger independent PTE eligibility. The practical implication for selection strategy is that companies should evaluate new indication approvals for PTE eligibility independently, particularly when the new indication involves a formulation or dosing route that differs from the original approval, because the boundaries of what constitutes a separate “product” under Section 156 are not always clear and have generated litigation.<\/p>\n\n\n\n

5. Are there drugs where the optimal PTE selection is a manufacturing process patent rather than a compound or method-of-treatment patent?<\/strong><\/h2>\n\n\n\n

Yes, and the most likely candidates are complex biologic drugs with difficult-to-replicate manufacturing processes. For a biologic where the compound “patent” is a sequence patent that faces validity challenges or where the molecule’s structure is sufficiently well-known that the sequence patent has limited term remaining, a manufacturing process patent covering the cell line, fermentation conditions, or purification steps may be both valid and difficult to design around. The commercial protection from a manufacturing process patent depends on whether biosimilar manufacturers can develop alternative production processes that achieve equivalent product quality without using the patented steps. For biosimilars subject to the FDA’s comparability framework, which requires demonstration that the biosimilar is highly similar to the reference product despite minor differences in manufacturing, a process patent that covers the only known route to producing the reference-like product is a meaningful exclusivity barrier. Companies with biologics in development should include manufacturing patents in their PTE candidate inventory analysis as a matter of course, not as an afterthought after compound and method patents have been exhausted.<\/p>\n\n\n\n

References<\/strong><\/h1>\n\n\n\n

[1] U.S. Patent and Trademark Office. (2023). Patent term extension study: Eligibility, calculation, and post-grant challenges. USPTO Office of Patent Legal Administration. https:\/\/www.uspto.gov\/patent\/laws-and-regulations\/patent-term-extension<\/p>\n\n\n\n

[2] DrugPatentWatch. (2024). Patent expiration, Orange Book, and exclusivity analytics platform. https:\/\/www.drugpatentwatch.com<\/p>\n\n\n\n

[3] Merck & Co., Inc. (2024). 2023 Annual Report and 10-K. SEC Edgar. https:\/\/www.sec.gov\/cgi-bin\/browse-edgar?action=getcompany&CIK=MRK<\/p>\n\n\n\n

[4] U.S. Patent and Trademark Office. (2023). Patent Trial and Appeal Board statistics: FY2023. PTAB. https:\/\/www.uspto.gov\/patents\/ptab\/stats<\/p>\n\n\n\n

[5] Warner-Lambert Company LLC v. Generics (UK) Ltd & Ors [2018] UKSC 56. UK Supreme Court. https:\/\/www.supremecourt.uk\/cases\/uksc-2016-0197.html<\/p>\n\n\n\n

[6] Bhattacharya, R., & Bhattacharya, S. (2021). Lipitor and the generic pharmaceutical industry: Lessons in authorized generics and patent cliff management. Journal of Generic Medicines, 17(2), 88-97. https:\/\/doi.org\/10.1177\/17411343211004832<\/p>\n\n\n\n

[7] Novartis AG v. Union of India & Others (2013) 6 SCC 1. Supreme Court of India. AIR 2013 SC 1311.<\/p>\n\n\n\n

[8] Savile, C. K., Janey, J. M., Mundorff, E. C., Moore, J. C., Tam, S., Jarvis, W. R., … & Huisman, G. W. (2010). Biocatalytic asymmetric synthesis of chiral amines from ketones applied to sitagliptin manufacture. Science, 329(5989), 305-309. https:\/\/doi.org\/10.1126\/science.1188934<\/p>\n\n\n\n

[9] Government Accountability Office. (2021). Drug industry: Profits, research and development spending, and merger and acquisition deals. GAO-21-282. https:\/\/www.gao.gov\/products\/gao-21-282<\/p>\n\n\n\n

[10] Biogen Inc. (2021). 2020 Annual Report. SEC Edgar. https:\/\/www.sec.gov\/cgi-bin\/browse-edgar?action=getcompany&CIK=BIIB<\/p>\n\n\n\n

[11] Tversky, A., & Kahneman, D. (1974). Judgment under uncertainty: Heuristics and biases. Science, 185(4157), 1124-1131. https:\/\/doi.org\/10.1126\/science.185.4157.1124<\/p>\n\n\n\n

[12] Regulation (EC) No. 469\/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products. Official Journal of the European Union L 152\/1. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX%3A32009R0469<\/p>\n\n\n\n

[13] Teva UK Ltd. v. Gilead Sciences Inc. (C-121\/17) [2018] ECLI:EU:C:2018:585. Court of Justice of the European Union. https:\/\/curia.europa.eu\/juris\/liste.jsf?num=C-121\/17<\/p>\n\n\n\n

[14] Grabowski, H., Long, G., Mortimer, R., & Boyo, A. (2014). Updated trends in US brand-name and generic drug competition. Journal of Medical Economics, 17(11), 836-844. https:\/\/doi.org\/10.3111\/13696998.2014.952387<\/p>\n\n\n\n

[15] Berndt, E. R., Conti, R. M., & Murphy, S. J. (2018). The landscape of US generic prescription drug markets, 2004-2016. NBER Working Paper Series, No. 23640. https:\/\/doi.org\/10.3386\/w23640<\/p>\n","protected":false},"excerpt":{"rendered":"

The Decision That Defines Decades of Revenue Somewhere between the FDA approval notice hitting a pharmaceutical company’s inbox and the […]<\/p>\n","protected":false},"author":1,"featured_media":37322,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-37321","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37321","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=37321"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37321\/revisions"}],"predecessor-version":[{"id":37323,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37321\/revisions\/37323"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/37322"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=37321"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=37321"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=37321"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}